The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
At least 18 years old Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme ECOG performance status score either 0, 1, or 2 Willing and able to provide written informed consent
Exclusion Criteria:
Greater than two prior cytotoxic regimens Laboratory values showing adequate function of bone marrow, liver, and kidneys Uncontrolled hypertension Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80
